-
Suzhou SmartNuclide Biopharmaceutical Secures $13.8 Million in Series C+ Funding to Advance Radiopharmaceutical Pipeline
•
Suzhou SmartNuclide Biopharmaceutical Co., Ltd, a leading developer of radiopharmaceuticals in China, has announced the completion of a Series C+ financing round worth RMB 100 million ($13.8 million). The round was led by Oriza Holdings, with significant contributions from YZ Capital, JianSu Capital, Leader Venture Capital, and returning investor RealHarmony…
-
Smartnuclide Biopharmaceutical Partners with Gosun Pharmaceuticals for rhTSH Market Promotion in China
•
Suzhou Smartnuclide Biopharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has entered into a business cooperation agreement with Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd, granting the latter exclusive market promotion rights for its recombinant human thyroid stimulating hormone (rhTSH) in the thyroid and breast surgery markets within China. The financial…
